Jun. 30 at 9:35 PM
$ABEO " ZEVASKYN (prademagene zamikeracel), developed by Abeona Therapeutics, reported a gross profit margin of 69% for Q1 2026, generating
$6.0 million in gross profit on
$8.7 million in net product revenue. For context, here are the recent financial details:Quarterly Revenue (Q1 2026):
$8.72 millionCost of Sales (Q1 2026):
$2.69 millionProjected Future Margins: Management and analysts project that ZEVASKYN's gross margins will settle between 80% and 85% as patient treatment volumes and economies of scale increase."
Over the next 12 months if no new treatment centers are added and the current ones were to average just 1 treatment per month, it would result in about
$215M in revenues and at 80% margin would contribute about
$170M towards an overhead of about
$120M or a profit of about
$50M.
Any estimates of what the share price should be then? I know it would be a lot more than
$6.
